Protara Therapeutics, Inc. 8-K

What Happened
Protara Therapeutics, Inc. (TARA) filed a Form 8-K on May 13, 2026 (Item 2.02) announcing its results of operations and financial condition for the quarter ended March 31, 2026. The company issued a press release dated May 13, 2026 (Exhibit 99.1) reporting the quarterly results; the press release is incorporated by reference into the 8-K.

Key Details

• Announcement date: May 13, 2026.
• Reporting period: quarter ended March 31, 2026.
• Disclosure type: Item 2.02 — Results of Operations and Financial Condition; press release attached as Exhibit 99.1.
• Filing accession: 0001213900-26-055462 (Form 8-K).

Why It Matters
This 8-K provides investors with Protara’s latest quarterly earnings and financial condition information (earnings, revenue, cash and related metrics are in the press release). Retail investors should review the attached press release for the specific revenue, net income (or loss), cash position, and any commentary on business progress or outlook, as these details can affect valuation and near‑term trading decisions. For fuller audited or condensed financial statements and management discussion, watch for the company’s subsequent periodic filings (e.g., Form 10-Q).